Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.
Blood (2009)
  • Steven I. Park, Fred Hutchinson Cancer Research Center
  • Jaideep Shenoi, Fred Hutchinson Cancer Research Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Donald K. Hamlin, University of Washington
  • Nural Orgun, Fred Hutchinson Cancer Research Center
  • Aimee L. Kenoyer, Fred Hutchinson Cancer Research Center
  • Shani M. Wilbur, Fred Hutchinson Cancer Research Center
  • Amanda Axtman, Fred Hutchinson Cancer Research Center
  • D. Scott Wilbur, University of Washington
  • Yukang Lin, Fred Hutchinson Cancer Research Center
  • Darrell R. Fisher, Pacific Northwest National Laboratory
  • Ajay K. Gopal, Fred Hutchinson Cancer Research Center
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
November 20, 2009
Citation Information
Steven I. Park, Jaideep Shenoi, John M. Pagel, Donald K. Hamlin, et al.. "Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease." Blood Vol. 114 Iss. 22 (2009) p. 2705 - 2705
Available at: http://works.bepress.com/john-pagel/219/